Suspension of trading of securities on AIM


 

TIDMYRK 
 
RNS Number : 7656P 
York Pharma plc 
31 March 2009 
 

31 March 2009 
 
 
York Pharma Plc 
 (the "Company") 
 
 
Suspension of trading of securities on AIM 
 
 
On 20 March 2009, the Board of the Company announced that it was in discussions 
with two potential offerors and that these discussions included the provision of 
the necessary short term funding facilities to allow the Company to continue 
trading through the period needed to complete any formal offer for the Company 
under the Takeover Code. 
 
 
It was also announced on 20 March 2009 that the publication of the Company's 
results for the financial year ended 30 September 2008 (the "Results") would 
only take place after the Company had secured its short term funding needs. 
Discussions with the parties continue. However, as such short term funding is 
not yet available, the Company will now not be able, as required by the AIM 
Rules, to publish its Results prior to 31 March 2009.  Accordingly, in 
accordance with the AIM Rules, all the Ordinary Shares and Warrants have been 
temporarily suspended today from trading on AIM, pending the publication of the 
Company's Results. 
 
 
The Board will provide a further update as and when appropriate. 
 
 
For more information please contact: 
 
 
+--------------------------------------+--------------------------------------+ 
| York Pharma Plc                      |            Tel: +44 (0) 1908 764 020 | 
| Richard Anderson, Chief Executive    |                                      | 
| Officer                              |                                      | 
| Ian Miscampbell, Chief Financial     |                                      | 
| Officer                              |                                      | 
+--------------------------------------+--------------------------------------+ 
|                                      |                                      | 
+--------------------------------------+--------------------------------------+ 
| Collins Stewart Europe Limited       |            Tel: +44 (0) 207 523 8350 | 
| Hugh Field / Adam Cowen              |                                      | 
+--------------------------------------+--------------------------------------+ 
|                                      |                                      | 
+--------------------------------------+--------------------------------------+ 
| Financial Dynamics                   |            Tel: +44 (0) 207 831 3113 | 
| Ben Brewerton / Emma Thompson        |                                      | 
+--------------------------------------+--------------------------------------+ 
 
 
Collins Stewart Europe Limited ("Collins Stewart") which is regulated in the 
United Kingdom by The Financial Services Authority is acting for the Company in 
relation to the matters described in this announcement and is not advising any 
other person, and accordingly will not be responsible to anyone other than the 
Company for providing the protections afforded to customers of Collins Stewart 
or for providing advice in relation to the matters described in this 
announcement. 
 
About York Pharma (YRK.L) 
York Pharma is a pharmaceutical group, established in 2003, which develops, 
markets and supplies branded dermatological products to pharmaceutical 
wholesalers, hospitals and general practitioners within the field of 
dermatology. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 SRSDGGFFMGMGLZZ

York Pharma (LSE:YRK)
過去株価チャート
から 5 2024 まで 6 2024